RayKnowChina Research Map
Shortlist

GuangzhouGuangzhou Medical University

First Affiliated Hospital of Guangzhou Medical University

广州医科大学附属第一医院

Listed for 13 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Guangzhou Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  3. Lung cancer肺癌186 papers led21 open trials led
  4. Osteosarcoma骨肉瘤0 papers led
  5. Neuroblastoma神经母细胞瘤1 paper led
  6. Lymphoma淋巴瘤1 paper led
  7. Congenital heart disease先天性心脏病2 papers led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  9. Takayasu arteritis大动脉炎0 papers led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化21 papers led
  11. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病3 papers led
  12. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  13. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Scoliosis, Hepatic echinococcosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 112025

24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & screeningInduction / concurrent chemotherapyImmunotherapy
Departments in papersENT / head & neck surgeryRadiation oncologyMedical oncology
Papers it led6
  1. Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis.2024Molecular biology reports
  3. Dosimetric comparison and evaluation of different convergence modes in nasopharyngeal carcinoma using VMAT treatment deliveries.2024PeerJFree full text
  4. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.2023Cancer immunology research
  5. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.2023Frontiers in immunologyFree full text
  6. Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
All its trials on ClinicalTrials.gov, any status4
  1. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  2. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  3. Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal CarcinomaStatus unknownNCT02211677Study siteStart 2014-08
  4. A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine RegimensStatus unknownNCT01762514Study sitePhase 2Start 2013-01
More papers found outside PubMed (not counted)9
  1. 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial2025Annals of Oncologyarticle
  2. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  3. From immune architecture to clinical decision: Insights into the TLS‐based RNA model for metastatic risk in nasopharyngeal carcinoma2025Clinical and Translational Discoveryarticle
  4. MicroRNA-195-5p suppresses metastasis by targeting VEGFA in nasopharyngeal carcinoma2024Research Squarepreprint
  5. Data from EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation2023Venue not listedother
  6. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.2023Journal of Clinical Oncologyconference-abstract
  7. Additional file 2 of Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway2021Figsharedataset
  8. M i R -182-5p I nduced by HIF-1α Promotes Tumorigenesis and Metastasis via Targeting ZFP36L1 in Nasopharyngeal Carcinoma2021Research Squarepreprint
  9. The Oncogenic Role of HIF-1α/miR-182-5p/ZFP36L1 Signaling Pathway in Nasopharyngeal Carcinoma2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 112025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapy
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 186 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
186
2021–2025
Trials led
50
any status, ClinicalTrials.gov
Open trials led
21
recruiting or about to
Open trials as a site
32
led by another institution
Papers led per year
2021: 303020212022: 242420222023: 313120232024: 414120242025: 53532025

17 hospitals in Guangzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 53

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06926790

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  2. Recruiting
    Multimodal AI-Guided Recovery Management After Lung Cancer Surgery
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07588737

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  3. Recruiting
    Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06383728

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  4. Recruiting
    Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06607796

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  5. Recruiting
    A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT06718972

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  6. Recruiting
    A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06775275

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  7. Recruiting
    Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06843707

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  8. Recruiting
    The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
    Phase
    N/A
    Started
    2024-07
    Posted
    Registry
    NCT06988579

    Age 40 years to 74 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  9. Recruiting
    Early Intervention Strategies for Lung Cancer
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06988943

    Age 40 years to 74 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  10. Recruiting
    Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
    Phase
    Phase 1/Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05777278

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  11. Recruiting
    Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06286150

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  12. Recruiting
    LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
    Phase
    Not given
    Started
    2019-06
    Posted
    Registry
    NCT06778512

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  13. Recruiting
    Non-risk Based Lang Cancer Screening With a One-off LDCT
    Phase
    N/A
    Started
    2015-12
    Posted
    Registry
    NCT04938804

    Age 40 years to 74 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  14. Not yet recruiting
    Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07303881

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  15. Not yet recruiting
    NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07318636

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  16. Not yet recruiting
    Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07352176

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  17. Not yet recruiting
    Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07395375

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  18. Not yet recruiting
    Tubeless Strategy for Enhanced Recovery After Sublobar Resection
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07409129

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  19. Not yet recruiting
    Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07413952

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  20. Not yet recruiting
    Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07150416

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  21. Not yet recruiting
    A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06422637

    Age 40 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  22. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  23. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  24. Recruiting
    Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07492342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou

  25. Recruiting
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07554339

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen

  26. Recruiting
    A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
    Phase
    Phase 2/Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07739186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou

  27. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  28. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  29. Recruiting
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07005102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan

  30. Recruiting
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07079475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin

  31. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  32. Recruiting
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07154706

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou

  33. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  34. Recruiting
    Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07610616

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  35. Recruiting
    PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07775820

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shenzhen, Wenzhou

  36. Recruiting
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    Phase
    Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06312137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou

  37. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  38. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  39. Recruiting
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06452277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen

  40. Recruiting
    A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06461156

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  41. Recruiting
    Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06497530

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  42. Recruiting
    Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT06518655

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan

  43. Recruiting
    Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
    Phase
    Not given
    Started
    2024-06
    Posted
    Registry
    NCT06528418

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  44. Recruiting
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06561386

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang

  45. Recruiting
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06564324

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  46. Recruiting
    Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06572540

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou

  47. Recruiting
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06119581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang

  48. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  49. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  50. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  51. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  52. Recruiting
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Posted
    Registry
    NCT04270591

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  53. Recruiting
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    Phase
    Phase 1
    Started
    2018-04
    Posted
    Registry
    NCT03460977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicineRadiation oncology
Papers it led186
  1. Symptom Clusters and Social Support in Patients With Lung Cancer Undergoing Anti-Programmed Death 1/Programmed Death Ligand 1 Immunotherapy: A Cross-sectional Analysis.2026Cancer nursing
  2. Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.2026European journal of nuclear medicine and molecular imaging
  3. Commentary: Ultrasound Measurements of Skeletal Muscle Predict Chemotherapy Toxicity in Non-Small Cell Lung Cancer.2026Nutrition and cancer
  4. Lactylation of HK2 facilitates cisplatin resistance in NSCLC by promoting cell migration, invasion, and glycolysis.2026Pathology, research and practice
  5. High-dimensional single-cell analysis evaluating effects of different airway management strategies on perioperative immune cells in non-small cell lung cancer surgery.2026Respiratory medicineRCT
  6. Objective Evaluation of Tubeless Thoracic Surgery in Early-Stage Lung Cancer Patients Using Multimodal Digital Device: A Prospective Study.2026The Annals of thoracic surgery
  7. Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer.2026The Annals of thoracic surgery
  8. Nebulized Inhalation of Engineered Extracellular Vesicles to Destruct Pre-metastatic Niche and Inhibit Postoperative Lung Metastasis in a Mouse Model.2025ACS nano
  9. Accuracy of Contrast-enhanced Ultrasonography with Perfluorobutane for Diagnosing Subpleural Lung Lesions.2025Academic radiology
  10. Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer.2025Acta pharmacologica SinicaFree full text
  11. Machine learning and discriminant analysis model for predicting benign and malignant pulmonary nodules.2025BMC medical informatics and decision makingFree full text
  12. Cost-effectiveness of risk model-based lung cancer screening in smokers and nonsmokers in China.2025BMC medicineFree full text
  13. Composite dietary antioxidant index and lung cancer risk: insights from the UK biobank.2025BMC public healthFree full text
  14. Global lung cancer burden attributable to air fine particulate matter and tobacco smoke exposure: spatiotemporal patterns, sociodemographic characteristics, and transnational inequalities from 1990 to 2021.2025BMC public healthFree full text
  15. Conservative management of postoperative incomplete lung torsion without reoperation: first case report with 2-year favorable outcomes.2025BMC surgeryFree full text
  16. Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial.2025Cell reports. MedicineFree full text
  17. A novel optimized orthotopic mouse model for brain metastasis with sustained cerebral blood circulation and capability of multiple delivery.2025Clinical & experimental metastasisFree full text
  18. LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study.2025Clinical and translational medicineFree full text
  19. Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.2025Clinical lung cancer
  20. PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer.2025Clinical nuclear medicine
  21. A-to-I edited SNHG3 promotes non-small cell lung cancer metastasis by promoting fatty acid oxidation and resisting ferroptosis.2025Communications biologyFree full text
  22. Prediction and immune infiltration analysis of lipid metabolism-related immune genes in the treatment of non-small cell lung cancer.2025Computers in biology and medicine
  23. Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.2025Current treatment options in oncology
  24. Induction chemoradiotherapy achieves long-term recurrence-free survival in locally advanced pulmonary lymphoepithelioma-like carcinoma: a case report and literature review.2025Frontiers in immunologyFree full text
  25. Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.2025Future oncology (London, England)Free full text
  26. Histomorphological and molecular spectrum of ciliated muconodular papillary tumors with implication for malignant potential: Insights from a literature review and series report.2025Human pathology
  27. Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events.2025Human vaccines & immunotherapeuticsFree full text
  28. Mannose Inhibits NSCLC Growth and Inflammatory Microenvironment by Regulating Gut Microbiota and Targeting OGT/hnRNP R/JUN/IL-8 Axis.2025International journal of biological sciencesFree full text
  29. Integrating a Multimodal Digital Device for Continuous Perioperative Monitoring in Patients With Lung Cancer Undergoing Thoracic Surgery: Development and Usability Study.2025JMIR mHealth and uHealthFree full text
  30. A Machine Learning Approach to Predicting Mortality Risk in Chemotherapy-Treated Lung Cancer: Machine Learning Model Development and Validation.2025JMIR medical informaticsFree full text
  31. Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.2025Journal for immunotherapy of cancerFree full text
  32. NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC.2025Journal for immunotherapy of cancerFree full text
  33. Advancements in diagnosis and treatment of lung adenocarcinoma patients under ECMO support: a case series and comprehensive literature review.2025Journal of cardiothoracic surgeryFree full text
  34. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  35. Comparative Study of Sonazoid and SonoVue Contrast-Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions.2025Journal of clinical ultrasound : JCU
  36. circPRMT10 regulated by QKI hypermethylation attenuates lung tumorigenesis induced by tobacco carcinogen NNK.2025Journal of hazardous materials
  37. Dynamic screening initiation using 16 plasma protein biomarkers with polygenic risk and PLCOm2012: a precision prevention framework for lung cancer.2025Journal of translational medicineFree full text
  38. The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.2025Lung cancer (Amsterdam, Netherlands)
  39. Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial.2025Lung cancer (Amsterdam, Netherlands)RCT
  40. Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.2025Lung cancer (Amsterdam, Netherlands)
  41. Causal association and potential mediator between lung cancer and tuberculosis: A Mendelian randomization study.2025Microbial pathogenesis
  42. RNF6 Inhibits Lung Adenocarcinoma Cell Proliferation by Promoting Cyclin D2 Degradation.2025Molecular cancer research : MCR
  43. Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients.2025Nature communicationsFree full text
  44. Comparison of three specimen collection techniques in tissue coagulum clot-based cell block preparation of endobronchial ultrasound-guided transbronchial needle aspiration.2025Pathology, research and practice
  45. The diagnostic performance and optimal strategy of cone beam CT-assisted bronchoscopy for peripheral pulmonary lesions: A systematic review and meta-analysis.2025Pulmonology
  46. CT-based Radiologic Ternary Classification Model in Predicting Pathologic Invasiveness of Pulmonary Nonsolid Nodules.2025Radiology
  47. How I Do It: Management of Pleural-attached Pulmonary Nodules in Low-Dose CT Screening for Lung Cancer.2025Radiology
  48. A rhodamine-coordinated iridium complex to overcome cisplatin-resistant cancer via regulating mitochondrial function triggered apoptosis and ferroptosis.2025Redox biologyFree full text
  49. A LncRNA panel within EpCAM-specific exosomes for noninvasive early diagnosing non-small cell lung cancer.2025Respiratory researchFree full text
  50. One-step diagnosis of infection and lung cancer using metagenomic sequencing.2025Respiratory researchFree full text
  51. Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII).2025Respirology (Carlton, Vic.)Free full text
  52. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial.2025Signal transduction and targeted therapyFree full text
  53. Night shift work and lung cancer risk: a prospective cohort study with mediator analysis from the UK Biobank.2025SleepFree full text
  54. Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer.2025The Annals of thoracic surgery
  55. Circular RNA circ_0004470 accelerates the occurrence of lung cancer by promoting DNA damage and cell cycle arrest.2025The Journal of biological chemistryFree full text
  56. Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.2025The Lancet. Oncology
  57. Efficacy and safety of novel airway balloon cryoablation system for malignant central airway obstruction: a prospective, multicentre, randomised, non-inferiority study.2025ThoraxRCT
  58. Diameter thresholds for pure ground-glass pulmonary nodules at low-dose CT screening: Chinese experience.2025ThoraxFree full text
  59. Intrapulmonary Epstein-Barr Virus-Associated Smooth Muscle Tumor after Bilateral Lung Transplantation: A Case Report.2025Transplantation proceedings
  60. Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I-III NSCLC.2025Tumori
  61. Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.2024Annals of clinical and laboratory science
  62. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma.2024Anti-cancer drugsFree full text
  63. Sub-lobar resection versus lobectomy for challenging intraoperative frozen sections in lung adenocarcinoma within 3 cm.2024Asian journal of surgery
  64. Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.2024BJS openFree full text
  65. A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.2024BMC cancerFree full text
  66. Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.2024BMC cancerFree full text
  67. Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis.2024BMC cancerFree full text
  68. Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report.2024BMC pulmonary medicineFree full text
  69. Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC.2024BMJ open respiratory researchFree full text
  70. [18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  71. Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyRCTFree full text
  72. LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.2024Cancer letters
  73. A clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratification of pulmonary nodules.2024Cell reports. MedicineFree full text
  74. EGFR -mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports.2024Chinese medical journalFree full text
  75. Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  76. Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study.2024Clinical lung cancer
  77. Impact of smoking cessation duration on lung cancer mortality: A systematic review and meta-analysis.2024Critical reviews in oncology/hematology
  78. Circular RNA circNIPBL regulates TP53-H179R mutations in NNK-induced bronchial epithelial carcinogenesis.2024Environment international
  79. Development of a nomogram for predicting survival in clinical T1N0M1 lung adenocarcinoma: a population-based study.2024European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  80. [64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window.2024European journal of nuclear medicine and molecular imaging
  81. The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study.2024European journal of nuclear medicine and molecular imagingFree full text
  82. Lower respiratory tract microbiome and lung cancer risk prediction in patients with diffuse lung parenchymal lesions.2024Frontiers in cellular and infection microbiologyFree full text
  83. Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.2024Frontiers in immunologyFree full text
  84. Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.2024International journal of medical sciencesFree full text
  85. Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study.2024International journal of surgery (London, England)Free full text
  86. High-Resolution CT Patterns of Anti-PD1 Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.2024Journal of computer assisted tomography
  87. Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.2024Journal of experimental & clinical cancer research : CRFree full text
  88. Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy.2024Journal of nanobiotechnologyFree full text
  89. Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis.2024Journal of translational medicineFree full text
  90. Exploring the molecular and immune-landscape of lung cancer associated with cystic airspaces.2024Molecular immunology
  91. Supervised training models with or without manual lesion delineation outperform clinicians in distinguishing pulmonary cryptococcosis from lung adenocarcinoma on chest CT.2024Mycoses
  92. Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma.2024Neoplasia (New York, N.Y.)Free full text
  93. Solitary pulmonary capillary hemangioma - An underrecognized rare tumor. Report of 32 new cases with literature review.2024Pathology, research and practice
  94. An original aneuploidy-related gene model for predicting lung adenocarcinoma survival and guiding therapy.2024Scientific reportsFree full text
  95. The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.2024Signal transduction and targeted therapyFree full text
  96. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.2024The Lancet. Oncology
  97. Solitary Renal Metastases From Stage IA Primary Lung Adenocarcinoma With Co-Alteration of EGFR, RB1, and MAP3K1: A Case Report.2024The clinical respiratory journalFree full text
  98. A Nomogram for Predicting Cancer-Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model.2024The clinical respiratory journalFree full text
  99. Circ0087385 promotes DNA damage in benzo(a)pyrene-induced lung cancer development by upregulating CYP1A1.2024Toxicological sciences : an official journal of the Society of Toxicology
  100. Neoadjuvant immunochemotherapy-a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma.2024World journal of surgical oncologyFree full text
  101. The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes.2024World journal of surgical oncologyFree full text
  102. Construction and Validation of a Prognostic Model Based on Novel Senescence-Related Genes in Non-Small Cell Lung Cancer Patients with Drug Sensitivity and Tumor Microenvironment.2023Advanced biology
  103. Behind the Indolent Facade: Uncovering the Molecular Features and Malignancy Potential in Lung Minimally Invasive Adenocarcinoma by Single-Cell Transcriptomics.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  104. Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma.2023AgingFree full text
  105. Diagnostic performance of diffusion-weighted imaging versus 18F-FDG PET/CT in differentiating pulmonary lesions: an updated meta-analysis of comparative studies.2023BMC medical imagingFree full text
  106. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.2023BMC medicineFree full text
  107. A surgical Decision-making scoring model for spontaneous ventilation- and mechanical ventilation-video-assisted thoracoscopic surgery in non-small-cell lung cancer patients.2023BMC surgeryFree full text
  108. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.2023Cancer medicineFree full text
  109. USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl.2023Clinical and translational medicineFree full text
  110. Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil.2023Clinical and translational medicineFree full text
  111. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment.2023Clinical and translational medicineFree full text
  112. A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study.2023Clinical drug investigation
  113. Sublobar resection reduces the risk of postoperative cognitive dysfunction compared with lobectomy.2023European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic SurgeryFree full text
  114. Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment.2023Frontiers in immunologyFree full text
  115. Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report.2023Human vaccines & immunotherapeuticsFree full text
  116. Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients.2023Human vaccines & immunotherapeuticsFree full text
  117. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.2023Immunopharmacology and immunotoxicology
  118. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.2023Journal for immunotherapy of cancerFree full text
  119. Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.2023Journal of cancer research and clinical oncologyFree full text
  120. The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis.2023Journal of cancer research and clinical oncologyFree full text
  121. Risk mapping of lung cancer: a comprehensive appraisal of published meta-analyses incorporating Mendelian randomization studies.2023Journal of cancer research and clinical oncologyFree full text
  122. Theranostic applications of selenium nanomedicines against lung cancer.2023Journal of nanobiotechnologyFree full text
  123. The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.2023Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  124. Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test.2023Lung cancer (Amsterdam, Netherlands)
  125. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.2023Lung cancer (Amsterdam, Netherlands)
  126. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.2023Lung cancer (Amsterdam, Netherlands)
  127. Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report.2023MedicineFree full text
  128. Accurate and Convenient Lung Cancer Diagnosis through Detection of Extracellular Vesicle Membrane Proteins via Förster Resonance Energy Transfer.2023Nano lettersFree full text
  129. 5G-Based Remote Virtual Bronchoscopic Navigation-Guided Transbronchial Lung Biopsy for Diagnosis of Lung Cancer: Description of 2 Cases.2023Respiration; international review of thoracic diseases
  130. Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study.2023The Lancet. Digital health
  131. The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.2023The clinical respiratory journalFree full text
  132. Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small-cell lung cancer.2023Thoracic cancerFree full text
  133. Current status of diagnosis and treatment of advanced non-small cell lung cancer in China during the COVID-19 pandemic.2022Annals of palliative medicine
  134. Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer.2022Annals of surgery
  135. Nonintubated Robotic-assisted Thoracic Surgery for Tracheal/Airway Resection and Reconstruction: Technique Description and Preliminary Results.2022Annals of surgeryFree full text
  136. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.2022Anti-cancer drugs
  137. Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.2022BMC cancerFree full text
  138. Characterization of the fatty acid metabolism-related genes in lung adenocarcinoma to guide clinical therapy.2022BMC pulmonary medicineFree full text
  139. GMFG (glia maturation factor gamma) inhibits lung cancer growth by activating p53 signaling pathway.2022BioengineeredFree full text
  140. Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion.2022Canadian respiratory journalFree full text
  141. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.2022Cancer medicineFree full text
  142. Video-assisted thoracic surgery for ambiguous lung or mediastinal masses in response assessments for hematological malignancies.2022Chinese medical journalFree full text
  143. The CT and PET/CT findings in primary pulmonary lymphoepithelioma-like carcinoma with pathological correlation: a study of 215 cases.2022Clinical radiology
  144. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.2022Critical reviews in oncology/hematology
  145. DNMT3A-mediated high expression of circ_0057504 promotes benzo[a]pyrene-induced DNA damage via the NONO-SFPQ complex in human bronchial epithelial cells.2022Environment international
  146. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation.2022European radiology
  147. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.2022Frontiers in immunologyFree full text
  148. Family Socioeconomic Position and Lung Cancer Risk: A Meta-Analysis and a Mendelian Randomization Study.2022Frontiers in public healthFree full text
  149. PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.2022International journal of biological sciencesFree full text
  150. Spontaneous Ventilation Video-Assisted Thoracoscopic Surgery for Geriatric Patients With Non-Small-Cell Lung Cancer.2022Journal of cardiothoracic and vascular anesthesia
  151. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Predicting and Monitoring the Response of Anti-Angiogenic Treatment in the Orthotopic Nude Mouse Model of Lung Adenocarcinoma.2022Journal of magnetic resonance imaging : JMRI
  152. Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.2022Journal of neurology
  153. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study.2022Molecular imaging and biology
  154. Hierarchical clock-scale hand-drawn mapping as a simple method for bronchoscopic navigation in peripheral pulmonary nodule.2022Respiratory researchFree full text
  155. Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer.2022Respiratory researchFree full text
  156. Involvement of m6A regulatory factor IGF2BP1 in malignant transformation of human bronchial epithelial Beas-2B cells induced by tobacco carcinogen NNK.2022Toxicology and applied pharmacology
  157. Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?2021American journal of respiratory and critical care medicineFree full text
  158. Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports.2021Annals of palliative medicine
  159. Values of Apparent Diffusion Coefficient and Lesion-to-Spinal Cord Signal Intensity in Diagnosing Solitary Pulmonary Lesions: Turbo Spin-Echo versus Echo-Planar Imaging Diffusion-Weighted Imaging.2021BioMed research internationalFree full text
  160. CUBIC-plus: An optimized method for rapid tissue clearing and decolorization.2021Biochemical and biophysical research communications
  161. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.2021Cancer
  162. Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.2021Cancer medicineFree full text
  163. Notch1/TAZ axis promotes aerobic glycolysis and immune escape in lung cancer.2021Cell death & diseaseFree full text
  164. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  165. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.2021Clinical lung cancer
  166. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.2021Critical reviews in oncology/hematology
  167. Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.2021Critical reviews in oncology/hematology
  168. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.2021Frontiers in immunologyFree full text
  169. Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence.2021Frontiers in immunologyFree full text
  170. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.2021Frontiers in immunologyFree full text
  171. Circ0001320 inhibits lung cancer cell growth and invasion by regulating TNFAIP1 and TPM1 expression through sponging miR-558.2021Human cell
  172. Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.2021Journal of cancer research and clinical oncologyFree full text
  173. Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.2021Journal of cancer research and clinical oncologyFree full text
  174. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.2021Lung cancer (Amsterdam, Netherlands)
  175. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.2021Lung cancer (Amsterdam, Netherlands)Free full text
  176. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.2021Molecular medicine reportsFree full text
  177. Lung cancer risk in patients with multiple sclerosis: a Mendelian randomization analysis.2021Multiple sclerosis and related disorders
  178. Pulmonary artery intimal sarcoma - A primeval or rediscovered tumor? A report of 14 new cases with literature review.2021Pathology, research and practice
  179. Feasibility and Safety of Radiofrequency Ablation Guided by Bronchoscopic Transparenchymal Nodule Access in Canines.2021Respiration; international review of thoracic diseases
  180. Rheumatoid arthritis and risk of lung cancer: Meta-analysis and Mendelian randomization study.2021Seminars in arthritis and rheumatism
  181. The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer.2021Signal transduction and targeted therapyFree full text
  182. Genetically predicted insomnia and lung cancer risk: a Mendelian randomization study.2021Sleep medicine
  183. Family History Associates With Micropapillary Pattern in Lung Adenocarcinoma ≤1.0 cm.2021The Annals of thoracic surgery
  184. Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.2021The Journal of clinical investigationFree full text
  185. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.2021The Lancet. Respiratory medicineRCT
  186. A genome-wide screen for differentially methylated long noncoding RNAs identified that lncAC007255.8 is regulated by promoter DNA methylation in Beas-2B cells malignantly transformed by NNK.2021Toxicology letters
Chinese-language papers (not in the count)18
  1. [Annual review of interventional pulmonology 2024].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  2. [Evaluation of 18F-fibroblast activation protein inhibitor-42 PET/CT in lymphangioleiomyomatosis and its correlation with vascular endothelial growth factor-D].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [An analysis of clinical and genetic feature in pulmonary artery sarcoma].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  4. [Annual therapeutic advances in advanced non-small cell lung cancer in 2024].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  5. [Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. [Molecular Subtype of Small Cell Lung Cancer: 
Challenge for Transforming into Clinical Practice].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  7. [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 
in Mouse Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  8. [Results of Lung Cancer Screening with Low-dose Computed Tomography 
and Exploration of Risk Factors in Guangzhou].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  9. [Cytology Smears of Rapid On-site Evaluation as Supplemental Material 
for Molecular Testing of Non-small Cell Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  10. [Brief analysis of diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  11. [Analysis of the efficacy and safety of dual immunotherapy in patients with driver gene and programmed death ligand-1 double negative advanced non-small cell lung cancer].2024Zhonghua yi xue za zhi
  12. [Analysis of Clinicopathological Features on Spread Through Air Spaces
of Lung Adenocarcinoma].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  13. [A case of metastatic breast cancer complicated by pulmonary tumor thrombotic microangiopathy].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  14. [Research Progress on Spread Through Air Spaces of Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  15. [Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: 
the Progress and Clinical Application].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  16. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].2022Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  17. [Analysis of the Relationship Between the Quality of Small Biopsy Specimens of 
Non-small Cell Lung Cancer and the Mutation Rate of EGFR Gene].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  18. [Predictive value of combined detection tumor markers in the diagnosis of lung cancer].2021Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status152
  1. Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain MetastasesNot yet recruitingNCT07413952Lead sponsorPhase 2Start 2026-04
  2. Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar ResectionNot yet recruitingNCT07395375Lead sponsorN/AStart 2026-03
  3. NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLCNot yet recruitingNCT07318636Lead sponsorPhase 1Start 2026-01
  4. Tubeless Strategy for Enhanced Recovery After Sublobar ResectionNot yet recruitingNCT07409129Lead sponsorN/AStart 2026-02
  5. Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung CancerNot yet recruitingNCT07303881Lead sponsorPhase 2Start 2026-02
  6. Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingNCT06926790Lead sponsorPhase 2Start 2025-06
  7. Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical StudyNot yet recruitingNCT07150416Lead sponsorPhase 2Start 2025-10
  8. Multimodal AI-Guided Recovery Management After Lung Cancer SurgeryRecruitingNCT07588737Lead sponsorN/AStart 2025-03
  9. The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer ScreeningRecruitingNCT06988579Lead sponsorN/AStart 2024-07
  10. Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell CarcinomaRecruitingNCT06383728Lead sponsorPhase 2Start 2024-04
  11. Early Intervention Strategies for Lung CancerRecruitingNCT06988943Lead sponsorN/AStart 2024-06
  12. A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLCRecruitingNCT06775275Lead sponsorPhase 2Start 2024-09
  13. Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.RecruitingNCT06843707Lead sponsorStart 2024-01
  14. A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid BiopsyNot yet recruitingNCT06422637Lead sponsorN/AStart 2024-06
  15. Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingNCT05777278Lead sponsorPhase 1/Phase 2Start 2023-07
  16. Efficacy and Safety of Single-port Surgical Robot System in Thoraic SurgeryRecruitingNCT06286150Lead sponsorN/AStart 2023-09
  17. LcProt: Proteomics Longitudinal Cohort Study on Lung CancerRecruitingNCT06778512Lead sponsorStart 2019-06
  18. Non-risk Based Lang Cancer Screening With a One-off LDCTRecruitingNCT04938804Lead sponsorN/AStart 2015-12
  19. Real-Time Non-Invasive Localization for Multiple Lung NodulesCompletedNCT07257549Lead sponsorN/AStart 2025-12
  20. Tubeless VATS for Lung Cancer SurgeryCompletedNCT07057531Lead sponsorN/AStart 2025-07
  21. Robotic-Assisted Navigation for Lung Nodule Localization: A Non-Inferiority StudyCompletedNCT07055997Lead sponsorN/AStart 2024-06
  22. A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus LobectomyCompletedNCT07288710Lead sponsorStart 2023-03
  23. Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.Status unknownNCT05946460Lead sponsorPhase 2Start 2023-08
  24. A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC PatientsStatus unknownNCT06118229Lead sponsorStart 2023-03
  25. Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCStatus unknownNCT04455594Lead sponsorPhase 2Start 2020-10
  26. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826Lead sponsorStart 2020-07
  27. A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLCStatus unknownNCT03700359Lead sponsorPhase 2Start 2019-03
  28. The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.Status unknownNCT04026841Lead sponsorPhase 2Start 2019-07
  29. A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung CancerStatus unknownNCT04181372Lead sponsorPhase 2Start 2019-12
  30. A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver GenesStatus unknownNCT03710629Lead sponsorStart 2018-07
  31. A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient SurvivalsStatus unknownNCT03710616Lead sponsorStart 2018-03
  32. Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With MicroinvasionStatus unknownNCT02011997Lead sponsorPhase 3Start 2013-12
  33. Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLCStatus unknownNCT02140333Lead sponsorPhase 3Start 2013-08
  34. A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung CancerStatus unknownNCT01872416Lead sponsorPhase 2Start 2012-10
  35. Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the LungStatus unknownNCT01872403Lead sponsorPhase 2Start 2012-10
  36. Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With LAP ProtectorStatus unknownNCT01104233Lead sponsorStart 2010-03
  37. Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung CancerStatus unknownNCT00923637Lead sponsorPhase 2Start 2009-06
  38. Radiofrequency Ablation Combined With Chemotherapy for Pulmonary TumorsStatus unknownNCT01105182Lead sponsorStart 2009-11
  39. Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung CancerStatus unknownNCT00862004Lead sponsorPhase 2Start 2008-12
  40. Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung CancerStatus unknownNCT01054482Lead sponsorPhase 2Start 2007-02
  41. Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT01051362Lead sponsorPhase 2Start 2006-02
  42. Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung CancerStatus unknownNCT00997724Lead sponsorPhase 2Start 1996-02
  43. Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary LesionsNot yet recruitingNCT07352176Lead (inferred)N/AStart 2026-02
  44. A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in ChinaRecruitingNCT06718972Lead (inferred)Start 2024-09
  45. Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without ChemoimmunotherapyRecruitingNCT06607796Lead (inferred)Phase 3Start 2024-03
  46. ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest SurgeryCompletedNCT07201077Lead (inferred)N/AStart 2025-01
  47. Safety and Feasibility of Remote Robotic Bronchoscopy for Peripheral Lung Cancer: A Multicenter, Proof-of-concept StudyCompletedNCT06613412Lead (inferred)N/AStart 2024-09
  48. A Single-arm Exploratory Study of Neoadjuvant TherapyStatus unknownNCT05527808Lead (inferred)N/AStart 2022-08
  49. Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLCStatus unknownNCT05001412Lead (inferred)Phase 1Start 2021-01
  50. The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung CancerActive, not recruitingNCT07638878Lead (inferred)Start 2020-11
  51. A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionRecruitingNCT07367529Study sitePhase 1/Phase 2Start 2026-02
  52. Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLCRecruitingNCT07492342Study sitePhase 2Start 2026-01
  53. A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)RecruitingNCT07739186Study sitePhase 2/Phase 3Start 2026-10
  54. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  55. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingNCT07554339Study sitePhase 3Start 2026-06
  56. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)RecruitingNCT07154706Study sitePhase 3Start 2025-08
  57. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Study sitePhase 3Start 2025-04
  58. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  59. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingNCT07079475Study sitePhase 1/Phase 2Start 2025-07
  60. Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsRecruitingNCT07610616Study siteStart 2025-12
  61. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07005102Study sitePhase 2/Phase 3Start 2025-08
  62. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Study sitePhase 3Start 2025-03
  63. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07111520Study sitePhase 1/Phase 2Start 2025-09
  64. PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung CancerRecruitingNCT07775820Study siteStart 2025-10
  65. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Study sitePhase 3Start 2024-10
  66. Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled BreathRecruitingNCT06518655Study siteStart 2024-06
  67. A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingNCT06461156Study sitePhase 1Start 2024-06
  68. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06452277Study sitePhase 3Start 2024-08
  69. Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled BreathRecruitingNCT06528418Study siteStart 2024-06
  70. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Study sitePhase 3Start 2024-05
  71. Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingNCT06497530Study sitePhase 2Start 2024-12
  72. A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingNCT06564324Study sitePhase 3Start 2024-11
  73. Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung CancerRecruitingNCT06572540Study siteN/AStart 2024-09
  74. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Study sitePhase 3Start 2024-06
  75. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingNCT06312137Study sitePhase 3Start 2024-04
  76. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Study sitePhase 3Start 2023-12
  77. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Study sitePhase 3Start 2023-12
  78. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Study sitePhase 3Start 2022-03
  79. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT05168566Study sitePhase 2Start 2022-09
  80. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Study sitePhase 2/Phase 3Start 2020-12
  81. Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingNCT04270591Study sitePhase 1/Phase 2Start 2019-07
  82. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingNCT03460977Study sitePhase 1Start 2018-04
  83. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCActive, not recruitingNCT06883630Study sitePhase 1Start 2025-03
  84. Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedNCT06924606Study sitePhase 2Start 2025-07
  85. HTA of NIVATS Based on RWECompletedNCT06574295Study siteStart 2024-08
  86. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Study sitePhase 3Start 2024-10
  87. Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 InhibitorStatus unknownNCT06310915Study siteStart 2023-03
  88. Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung CancerStatus unknownNCT05987345Study siteN/AStart 2023-07
  89. Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerCompletedNCT05577702Study sitePhase 2Start 2023-03
  90. To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)Status unknownNCT06341660Study sitePhase 2Start 2023-05
  91. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active, not recruitingNCT05555732Study sitePhase 3Start 2023-01
  92. A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLCActive, not recruitingNCT06443684Study siteStart 2023-05
  93. A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung CancerStatus unknownNCT06331650Study sitePhase 2Start 2023-08
  94. A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Study sitePhase 2Start 2023-06
  95. Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerStatus unknownNCT05513664Study siteStart 2022-09
  96. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  97. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerStatus unknownNCT05042375Study sitePhase 3Start 2022-09
  98. TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Study sitePhase 1/Phase 2Start 2022-03
  99. Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05502237Study sitePhase 3Start 2022-10
  100. AP-L1898 Capsule in Patients With Non-small Cell Lung CancerTerminatedNCT04993391Study sitePhase 1/Phase 2Start 2021-07
  101. Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCCompletedNCT04768075Study sitePhase 3Start 2021-05
  102. A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingNCT04603807Study sitePhase 3Start 2021-09
  103. Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Study sitePhase 4Start 2021-12
  104. Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung TumorsCompletedNCT04619472Study siteN/AStart 2021-01
  105. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Study sitePhase 2Start 2021-07
  106. A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminatedNCT04308785Study sitePhase 2Start 2021-12
  107. The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung CancerCompletedNCT04206787Study siteStart 2020-05
  108. A Study of Smoking Cessation Patterns in Participants Undergoing Lung SurgeryCompletedNCT04313361Study siteStart 2020-05
  109. A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive BiomarkersStatus unknownNCT04462185Study siteStart 2020-07
  110. A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Study sitePhase 3Start 2020-01
  111. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Study sitePhase 3Start 2020-02
  112. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)CompletedNCT04194203Study sitePhase 3Start 2020-04
  113. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04005716Study sitePhase 3Start 2019-07
  114. A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCStatus unknownNCT04033354Study sitePhase 3Start 2019-08
  115. Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyStatus unknownNCT04085250Study sitePhase 2Start 2019-11
  116. A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Study sitePhase 3Start 2019-05
  117. A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedNCT03535740Study sitePhase 2Start 2019-01
  118. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedNCT03596866Study sitePhase 3Start 2019-04
  119. A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCStatus unknownNCT04167774Study sitePhase 2Start 2019-07
  120. Long Term Safety Observation of Crizotinib in Chinese NSCLC PopulationTerminatedNCT03672643Study sitePhase 4Start 2019-01
  121. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Study sitePhase 1/Phase 2Start 2019-07
  122. Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03972189Study sitePhase 2Start 2019-07
  123. Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFRStatus unknownNCT05767866Study sitePhase 1/Phase 2Start 2018-03
  124. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Study sitePhase 3Start 2018-11
  125. Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip PlatformStatus unknownNCT03692442Study siteStart 2018-05
  126. Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating AnesthesiaStatus unknownNCT03432637Study sitePhase 3Start 2018-03
  127. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Study sitePhase 3Start 2018-08
  128. Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruitingNCT03539536Study sitePhase 2Start 2018-10
  129. Feasibility Study of the RF Ablation Catheter to Ablate Lung TumorsTerminatedNCT03272971Study siteN/AStart 2017-12
  130. A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Study sitePhase 2/Phase 3Start 2017-09
  131. Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)CompletedNCT03059797Study sitePhase 2Start 2017-03
  132. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaCompletedNCT03059641Study siteStart 2017-02
  133. NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLCStatus unknownNCT03029273Study sitePhase 1Start 2017-03
  134. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Study sitePhase 3Start 2016-07
  135. A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)CompletedNCT02763579Study sitePhase 3Start 2016-06
  136. A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)CompletedNCT02657434Study sitePhase 3Start 2016-04
  137. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Study sitePhase 3Start 2016-08
  138. Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2CompletedNCT02867371Study siteN/AStart 2016-08
  139. Plasmodium Immunotherapy for Lung CancerStatus unknownNCT02786589Study sitePhase 1/Phase 2Start 2016-06
  140. Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Study sitePhase 2Start 2016-03
  141. Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)CompletedNCT02388919Study sitePhase 2/Phase 3Start 2015-02
  142. Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]CompletedNCT02486718Study sitePhase 3Start 2015-10
  143. Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Study sitePhase 3Start 2015-06
  144. Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaStatus unknownNCT02103257Study sitePhase 4Start 2014-03
  145. Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCCompletedNCT01945021Study sitePhase 2Start 2013-09
  146. Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving ChemotherapyCompletedNCT02005458Study sitePhase 2Start 2013-12
  147. A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsCompletedNCT01639001Study sitePhase 3Start 2012-09
  148. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous ChemotherapyCompletedNCT01364012Study sitePhase 3Start 2011-05
  149. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerCompletedNCT03117335Study sitePhase 3Start 2011-11
  150. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian PopulationTerminatedNCT01015443Study sitePhase 3Start 2009-12
  151. A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe ObstructionCompletedNCT03448146Study sitePhase 3Start 2009-08
  152. Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung CancerCompletedNCT00883675Study sitePhase 4Start 2009-05

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 1 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Guangzhou for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    Phase
    Phase 1
    Started
    2018-04
    Posted
    Registry
    NCT03460977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K/AKT/PD-L1 axis.2024International immunopharmacology
All its trials on ClinicalTrials.gov, any status10
  1. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingNCT03460977Study sitePhase 1Start 2018-04
  2. A Study of Brentuximab Vedotin in Adults With CD30-positive LymphomaCompletedNCT04837222Study siteStart 2021-06
  3. A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT05023980Study sitePhase 3Start 2021-09
  4. Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLLStatus unknownNCT02546739Study sitePhase 1Start 2021-03
  5. Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibCompletedNCT05068440Study sitePhase 2Start 2021-08
  6. A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)Status unknownNCT04324879Study sitePhase 2Start 2020-05
  7. A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Study sitePhase 2Start 2019-04
  8. A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedNCT03535740Study sitePhase 2Start 2019-01
  9. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Study sitePhase 3Start 2016-08
  10. R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell LymphomaStatus unknownNCT02428751Study sitePhase 3Start 2015-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 2 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.08%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

12 hospitals in Guangzhou for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR AntibodiesNot yet recruitingNCT07858175Study siteStart 2026-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Guangzhou for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 21 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 2.1%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 7720222023: 5520232024: 4420242025: 332025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRheumatology & immunologyGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led21
  1. Machine learning-based integration identifies plasma cells-related gene signature ST6GAL1 in idiopathic pulmonary fibrosis.2025BMC pulmonary medicineFree full text
  2. Impaired ciliogenesis in small airway epithelial cells involves in the development of idiopathic pulmonary fibrosis.2025Biochimica et biophysica acta. Molecular basis of disease
  3. Survival and early outcomes following lung transplantation for interstitial lung disease associated with non-scleroderma connective tissue disease: a national cohort study.2025Clinical and experimental rheumatology
  4. Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.2024BMC cancerFree full text
  5. Multiomic analysis of monocyte-derived alveolar macrophages in idiopathic pulmonary fibrosis.2024Journal of translational medicineFree full text
  6. Characterizing the lavage and serum cytokine profiles of interstitial pneumonia with autoimmune features and their implications for progressive fibrosis.2024Rheumatology (Oxford, England)Free full text
  7. Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K/AKT/mTOR pathway.2024Signal transduction and targeted therapyFree full text
  8. Assessing the genetic relationship between gastroesophageal reflux disease and chronic respiratory diseases: a mendelian randomization study.2023BMC pulmonary medicineFree full text
  9. Therapeutic effects of fatty acid binding protein 1 in mice with pulmonary fibrosis by regulating alveolar epithelial regeneration.2023BMJ open respiratory researchFree full text
  10. Repairing Mechanisms for Distal Airway Injuries and Related Targeted Therapeutics for Chronic Lung Diseases.2023Cell transplantationFree full text
  11. LncRNA GAS5 suppresses TGF-β1-induced transformation of pulmonary pericytes into myofibroblasts by recruiting KDM5B and promoting H3K4me2/3 demethylation of the PDGFRα/β promoter.2023Molecular medicine (Cambridge, Mass.)Free full text
  12. Mediators of the association between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis.2023The European respiratory journal
  13. Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.2022Cellular and molecular life sciences : CMLSFree full text
  14. Outcomes after lung transplantation among Chinese patients with connective tissue disease-associated interstitial lung disease and pulmonary hypertension: a retrospective cohort study.2022Clinical and experimental rheumatology
  15. Identification and validation of autophagy-related gene expression for predicting prognosis in patients with idiopathic pulmonary fibrosis.2022Frontiers in immunologyFree full text
  16. Detection of interstitial pneumonia with autoimmune features and idiopathic pulmonary fibrosis are enhanced by involvement of matrix metalloproteinases levels and clinical diagnosis.2022Journal of clinical laboratory analysisFree full text
  17. Effects of bone morphogenetic protein 4 on TGF-β1-induced cell proliferation, apoptosis, activation and differentiation in mouse lung fibroblasts via ERK/p38 MAPK signaling pathway.2022PeerJFree full text
  18. Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts.2022The European respiratory journalFree full text
  19. Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.2022The European respiratory journalFree full text
  20. Deleterious Role of Th9 Cells in Pulmonary Fibrosis.2021CellsFree full text
  21. Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases.2021Frontiers in immunologyFree full text
Earlier papers (2016–2020)5
  1. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.2020BMC pulmonary medicine
  2. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.2020Toxicology letters
  3. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.2019Respiration; international review of thoracic diseases
  4. The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study.2019Scientific reports
  5. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis.2016Stem cell research & therapy
All its trials on ClinicalTrials.gov, any status14
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07933133Study sitePhase 2Start 2026-12
  4. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  5. Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06230822Study sitePhase 1Start 2024-03
  6. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  7. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  8. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  9. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis SubjectsCompletedNCT05895565Study sitePhase 1Start 2023-05
  10. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  11. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  12. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  13. Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001CompletedNCT05657184Study sitePhase 1Start 2021-07
  14. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 3 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 6.7%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

2 hospitals in Guangzhou for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Guangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Guangzhou for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Research progress of serrated polyposis syndrome].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广州医科大学附属第一医院

First Affiliated Hospital of Guangzhou Medical University

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First affiliated hospital of Guangzhou Medical University

Suggest a correctionDownload the data